Form 4: ResMed CFO Exercises Options, Sells Shares Under 10b5-1 Plan

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

Summary

• Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), engaged in two transactions on September 2, 2025.
• He exercised options to acquire 2,000 shares of ResMed Common Stock at an exercise price of $101.64 per share.
• Concurrently, he sold 3,000 shares of ResMed Common Stock at a price of $270.77 per share.
• Both transactions were conducted pursuant to a Rule 10b5-1 plan, which was adopted on February 19, 2025.
• Following these transactions, Mr. Sandercock directly beneficially owns 87,745 shares of ResMed Common Stock and 4,000 derivative securities (options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there is a net sale of shares, it's under a pre-arranged 10b5-1 plan, which mitigates concerns about opportunistic selling. The officer also realized a significant profit from the option exercise, which is a positive for executive compensation.

Positives

• The exercise of stock options indicates the officer's realization of value from their compensation package.
• The transactions were executed under a pre-arranged Rule 10b5-1 plan, which suggests the sale was not based on new, non-public information and is a common practice for executive liquidity and diversification.

Negatives

• The net reduction of 1,000 shares in direct beneficial ownership (3,000 sold vs. 2,000 acquired) could be perceived as a slight decrease in insider alignment, although it is a common practice for executives to sell shares to cover taxes and for personal financial planning.

Future Outlook

NA

Industry Context

This filing details routine insider transactions by a key executive and does not provide information directly related to broader industry trends or competitive positioning. Such transactions are common across all industries for executive compensation and personal financial management.

Stakeholder Impact

• Shareholders: May view the net sale of shares as a minor signal, though the 10b5-1 plan reduces its significance. The realization of profit by a key executive can be seen as a positive for executive alignment with shareholder interests.

Key Dates

Keywords

ResMed, RMD, Form 4, Insider Trading, Stock Options, CFO, Brett Sandercock, 10b5-1 plan, Executive Compensation